文献速递肺栓塞与肺血管病

肺动脉高压药物治疗中血氧饱和度下降患者结局

Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs.
PubMed 文献 · Eur Respir J · 2021-11-04

该回顾性研究基于法国肺动脉高压注册库,分析719例PAH患者,发现173例(24%)在PAH药物治疗期间出现动脉血氧饱和度下降≥3%。这些患者诊断时年龄更大、一氧化碳弥散量更低、6分钟步行距离更短,再评估时达到ESC/ERS低风险标准的比例更低、长期氧疗启动更多(16% vs 5%,p<0.001),且生存更差(HR 1.81,95%CI 1.43-2.34;p<0.0001)。

要点

  • PAH药物治疗中约24%患者出现SaO2下降≥3%。
  • SaO2下降≥3%与更差生存独立相关(HR 1.81)。
  • 此类患者再评估达低风险标准比例更低、氧疗启动更多。

核心结论

  • 接受PAH药物治疗的患者中,较大比例出现SaO2下降≥3%,且与更差长期结局和生存降低相关。

研究设计与样本

  • 法国肺动脉高压注册库的回顾性研究,共审查719例PAH患者。
  • 排除与先天性心脏病相关的PAH及具有明显静脉/毛细血管受累特征的PAH。

主要发现

  • 173例(24%)患者出现SaO2下降≥3%。
  • 与未出现SaO2下降≥3%者相比,这些患者诊断时年龄更大、DLCO更低、6分钟步行距离更短。
  • 再评估时达到ESC/ERS低风险标准的比例显著更低,启动长期氧疗者更多(16% vs 5%;p<0.001)。
  • SaO2下降≥3%与更差生存相关(HR 1.81,95%CI 1.43-2.34;p<0.0001)。
  • 多变量Cox分析中,SaO2下降≥3%是独立于诊断时年龄和随访时ESC/ERS风险分层的预后因素。

关键数值与推荐

  • SaO2下降≥3%为暴露定义。
  • 长期氧疗启动比例:SaO2下降≥3%组16% vs 未下降组5%(p<0.001)。
  • 生存风险比:HR 1.81(95%CI 1.43-2.34;p<0.0001)。

临床怎么用

  • PAH药物治疗期间应监测SaO2变化,下降≥3%提示预后较差。
  • 对出现SaO2下降≥3%的患者,可考虑更密切随访并评估长期氧疗指征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drugs approved for the treatment of pulmonary arterial hypertension (PAH) improve long-term outcomes. These drugs have pulmonary vasodilator properties which may potentially cause a decrease in arterial oxyhaemoglobin saturation (S aO2 ) in some patients. The present retrospective study of the French Pulmonary Hypertension Registry aimed to describe the clinical characteristics and outcomes of patients showing a ≥3% decrease in S aO2 while treated with PAH drugs. METHODS: We reviewed 719 PAH patients. The exclusion criteria were PAH associated with congenital heart disease and PAH with overt features of venous/capillaries involvement. RESULTS: 173 (24%) patients had a ≥3% decrease in S aO2 . At diagnosis, they were older with a lower diffusing capacity of the lung for carbon monoxide and a shorter 6-min walk distance compared with those who did not display a ≥3% decrease in S aO2 . The percentage of patients meeting the European Society of Cardiology/European Respiratory Society (ESC/ERS) low-risk criteria at re-evaluation was significantly lower in those with a ≥3% decrease in S aO2 and more patients started long-term oxygen therapy in this group (16% versus 5%; p<0.001). A ≥3% decrease in S aO2 was associated with a poorer survival (hazard ratio 1.81, 95% CI 1.43-2.34; p<0.0001). In a multivariate Cox analysis, a ≥3% decrease in S aO2 was a prognostic factor independent of age at diagnosis and ESC/ERS risk stratification at follow-up. CONCLUSIONS: When treated with PAH drugs, a large subset of patients experience a ≥3% decrease in S aO2 , which is associated with worse long-term outcomes and reduced survival.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Valentin S, Maurac A, Sitbon O, et al. Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. Eur Respir J. 2021. PMID: 33875491. doi:10.1183/13993003.04066-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。